Thiotepa Riemser Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastické činidlá - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Siklos Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

siklos

theravia - hydroxykarbamid - anémia, kosáčiková bunka - antineoplastické činidlá - siklos je indikovaný na prevenciu opakujúce sa bolestivé vaso-occlusive kríz, vrátane akútnych hrudníka syndróm v detských a dospelých pacientov, ktorí trpia symptomatickou kosáčikovitá syndróm.

Opfolda Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

opfolda

amicus therapeutics europe limited - miglustat - glykogénová choroba typu ii - ostatné produkty tráviaceho traktu a metabolizmu - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Galafold Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

galafold

amicus therapeutics europe limited - migalastat hydrochloride - fabryho choroba - migalastat - galafold je indikovaný na dlhodobú liečbu dospelých a dospievajúcich vo veku 16 rokov a starších s potvrdenou diagnózou fabryho choroby (deficit α-galaktozidázy a), a ktorí majú prístupnejší mutácie.

Pombiliti Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

pombiliti

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).